Novartis | NOVN - أصول متداولة





أصول متداولة تغيير تاريخ
AbbVie USD 33.67B 140M 2026-06
Alcon AG USD 6.62B 171M 2026-03
Almirall EUR 747.1M 33.12M 2026-06
Amgen USD 34.96B 3.49B 2026-06
AstraZeneca USD 27.97B 1.65B 2026-06
Autolus Therapeutics Ltd USD 368.84M 67.08M 2026-03
Bayer EUR 35.3B 2.39B 2026-03
Biogen USD 7.31B 1.88B 2026-06
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Eli Lilly USD 64.67B 9.84B 2026-06
Fresenius EUR 11.61B 456M 2026-06
Fresenius Medical Care EUR 8.11B 209.55M 2026-03
Genmab DKK 2.8B 228M 2026-06
Gilead Sciences USD 12.53B 6.11B 2026-06
GlaxoSmithKline GBP 17.56B 202M 2026-06
GRIFOLS EUR 5.31B 51M 2026-06
Hikma Pharmaceutical USD 2.64B 86M 2025-12
J&J USD 59.77B 601M 2026-06
Lakefront Biotherapeutics EUR 3.06B 18.72M 2026-03
Lonza CHF 8B 3.41B 2025-12
Merck EUR 14.16B 932M 2026-03
Merck USD 36.68B 1.66B 2026-06
Novartis USD 27.35B 744M 2026-06
Novartis USD 26.61B 3.85B 2026-03
Novo Nordisk DKK 208.7B 31.38B 2026-06
Orion EUR 1.2B 211.8M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
Philips EUR 9.33B 454M 2026-06
Recordati EUR 1.76B 29.78M 2026-06
Regeneron Pharmaceuticals USD 18.45B 236.8M 2026-06
Roche Holding CHF 35.44B 3.29B 2026-06
Sanofi EUR 31.52B 1.36B 2026-06
UCB EUR 6.05B 733M 2025-12